{"id":743834,"date":"2013-03-09T12:50:00","date_gmt":"2013-03-09T12:50:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/"},"modified":"2023-03-22T00:04:40","modified_gmt":"2023-03-22T04:04:40","slug":"results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/","title":{"rendered":"Results from HPS2-THRIVE Study of TREDAPTIVE\u2122 (extended-release niacin\/laropiprant) Presented at American College of Cardiology Scientific Sessions"},"content":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that researchers from the Clinical Trial Service Unit at<br \/>\n      Oxford University presented results from the HPS2-THRIVE (<b>H<\/b>eart <b>P<\/b>rotection<br \/>\n      <b>S<\/b>tudy 2-<b>T<\/b>reatment of <b>H<\/b>DL to <b>R<\/b>educe the <b>I<\/b>ncidence<br \/>\n      of <b>V<\/b>ascular <b>E<\/b>vents) study of TREDAPTIVE<sup>\u2122<\/sup>(extended-release<br \/>\n      niacin\/laropiprant) during a late-breaking clinical trials session at<br \/>\n      the American College of Cardiology 62<sup>nd<\/sup> Annual Scientific<br \/>\n      Sessions (abstract 300-14). HPS2-THRIVE was independently conducted by<br \/>\n      the Clinical Trial Service Unit at Oxford University, the regulatory<br \/>\n      sponsor of the trial, and funded by Merck.\n    <\/p>\n<p>\n      Merck previously announced that the study did not meet its primary<br \/>\n      endpoint (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fpress-release%2Fprescription-medicine-news%2Fmerck-announces-hps2-thrive-study-tredaptive-extended-relea&#038;esheet=50587385&#038;lan=en-US&#038;anchor=December+20%2C+2012+news+release&#038;index=1&#038;md5=05a64fabda2da28dff12c8516c918fdf\">December<br \/>\n      20, 2012 news release<\/a>). Adding TREDAPTIVE to statin therapy did not<br \/>\n      significantly further reduce the risk of major vascular events compared<br \/>\n      to statin therapy in patients at high risk of cardiovascular events.<br \/>\n      Additionally, there was a statistically significant increase in the<br \/>\n      incidence of some types of non-fatal serious adverse events in the group<br \/>\n      that received TREDAPTIVE. Merck announced in January that it was taking<br \/>\n      steps to suspend the availability of TREDAPTIVE in countries where the<br \/>\n      medicine has been approved (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fpress-release%2Fresearch-and-development-news%2Fmerck-provides-update-next-steps-tredaptive-extended-rel&#038;esheet=50587385&#038;lan=en-US&#038;anchor=January+11%2C+2013+news+release&#038;index=2&#038;md5=152e5f50d17af164e50dee6a439259ae\">January<br \/>\n      11, 2013 news release<\/a>). TREDAPTIVE is not approved in the United<br \/>\n      States.\n    <\/p>\n<p>\n      The results of HPS2-THRIVE in 25,673 patients were presented by<br \/>\n      Professor Jane Armitage, FFPH, FRCP, professor of clinical trials and<br \/>\n      epidemiology, Oxford University and the primary investigator for the<br \/>\n      HPS2-THRIVE study. In the trial, the composite primary endpoint of major<br \/>\n      vascular events (coronary death, non-fatal heart attack, stroke or any<br \/>\n      arterial revascularization) occurred in 13.2 percent of the patients<br \/>\n      taking TREDAPTIVE plus statin therapy (n=1,696) compared to 13.7 percent<br \/>\n      of the patients taking statin therapy alone (n=1,758) after a median 3.9<br \/>\n      years of follow-up. This corresponded to a risk ratio of 0.96 (95<br \/>\n      percent CI: 0.90-1.03; p=0.29).\n    <\/p>\n<p>\n      As previously disclosed, there were statistically significant increases<br \/>\n      in non-fatal serious adverse events observed in patients taking<br \/>\n      TREDAPTIVE plus statin therapy compared to patients taking placebo plus<br \/>\n      statin therapy. These events included: diabetic complications, new onset<br \/>\n      diabetes, infection, gastrointestinal, musculoskeletal, bleeding<br \/>\n      (including gastrointestinal and intracranial) and skin. There was also a<br \/>\n      small excess in heart failure.\n    <\/p>\n<p>\n      \u201cMerck has a long and proud history of supporting major outcomes studies<br \/>\n      to investigate challenging scientific questions and advance our<br \/>\n      collective understanding of cardiovascular medicine,\u201d said Michael<br \/>\n      Mendelsohn, M.D., senior vice president, cardiovascular medicine, Merck<br \/>\n      Research Laboratories. \u201cThe results of HPS2-THRIVE add substantially to<br \/>\n      the body of scientific knowledge in this important therapeutic area.\u201d\n    <\/p>\n<p>\n      <b>About HPS2-THRIVE<\/b>\n    <\/p>\n<p>\n      As noted,<b> <\/b>HPS2-THRIVE (Clinicaltrials.gov identifier: NCT<br \/>\n      00461630) was independently conducted by the Clinical Trial Service Unit<br \/>\n      at Oxford University and funded by Merck. The study enrolled 25,673<br \/>\n      patients considered to be at high risk for cardiovascular events. Of<br \/>\n      those enrolled, 14,741 were from Europe (the United Kingdom and<br \/>\n      Scandinavia) and 10,932 were from China. HPS2-THRIVE compared<br \/>\n      extended-release niacin and laropiprant (a flushing pathway inhibitor)<br \/>\n      plus statin therapy versus statin therapy. It was not designed to assess<br \/>\n      directly the separate effects of either extended-release niacin or<br \/>\n      laropiprant.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50587385&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=3&#038;md5=80c5cd66f095bb7bad7491337be0c1e5\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50587385&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=4&#038;md5=d686c00dbe0ab9220b6ba3cc2ee4d53f\">www.sec.gov<\/a>).\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20130309005046r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 908-423-5042<br \/>Skip Irvine,        267-305-5397<br \/>or<br \/>Investors:<br \/>Carol Ferguson, 908-423-4465<br \/>Justin        Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers from the Clinical Trial Service Unit at Oxford University presented results from the HPS2-THRIVE ( H eart P rotection S tudy 2- T reatment of H DL to R educe the I ncidence of V ascular E vents) study of TREDAPTIVE \u2122 (extended-release niacin\/laropiprant) during a late-breaking clinical trials session at the American College of Cardiology 62 nd Annual Scientific Sessions (abstract 300-14). HPS2-THRIVE was independently conducted by the Clinical Trial Service Unit at Oxford University, the regulatory sponsor of the trial, and funded by Merck. Merck previously announced that the study did not meet its primary endpoint (December 20, 2012 news release). Adding TREDAPTIVE to statin therapy did not significantly further reduce the risk of major vascular events compared to statin therapy in patients at high risk of cardiovascular events. Additionally, there was a statistically significant<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-743834","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Results from HPS2-THRIVE Study of TREDAPTIVE\u2122 (extended-release niacin\/laropiprant) Presented at American College of Cardiology Scientific Sessions - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Results from HPS2-THRIVE Study of TREDAPTIVE\u2122 (extended-release niacin\/laropiprant) Presented at American College of Cardiology Scientific Sessions - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers from the Clinical Trial Service Unit at Oxford University presented results from the HPS2-THRIVE ( H eart P rotection S tudy 2- T reatment of H DL to R educe the I ncidence of V ascular E vents) study of TREDAPTIVE \u2122 (extended-release niacin\/laropiprant) during a late-breaking clinical trials session at the American College of Cardiology 62 nd Annual Scientific Sessions (abstract 300-14). HPS2-THRIVE was independently conducted by the Clinical Trial Service Unit at Oxford University, the regulatory sponsor of the trial, and funded by Merck. Merck previously announced that the study did not meet its primary endpoint (December 20, 2012 news release). Adding TREDAPTIVE to statin therapy did not significantly further reduce the risk of major vascular events compared to statin therapy in patients at high risk of cardiovascular events. Additionally, there was a statistically significant\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:40+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130309005046r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\\\/\",\"name\":\"Results from HPS2-THRIVE Study of TREDAPTIVE\u2122 (extended-release niacin\\\/laropiprant) Presented at American College of Cardiology Scientific Sessions - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130309005046r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2013-03-09T12:50:00+00:00\",\"dateModified\":\"2023-03-22T04:04:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130309005046r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130309005046r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Results from HPS2-THRIVE Study of TREDAPTIVE\u2122 (extended-release niacin\\\/laropiprant) Presented at American College of Cardiology Scientific Sessions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Results from HPS2-THRIVE Study of TREDAPTIVE\u2122 (extended-release niacin\/laropiprant) Presented at American College of Cardiology Scientific Sessions - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/","og_locale":"en_US","og_type":"article","og_title":"Results from HPS2-THRIVE Study of TREDAPTIVE\u2122 (extended-release niacin\/laropiprant) Presented at American College of Cardiology Scientific Sessions - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers from the Clinical Trial Service Unit at Oxford University presented results from the HPS2-THRIVE ( H eart P rotection S tudy 2- T reatment of H DL to R educe the I ncidence of V ascular E vents) study of TREDAPTIVE \u2122 (extended-release niacin\/laropiprant) during a late-breaking clinical trials session at the American College of Cardiology 62 nd Annual Scientific Sessions (abstract 300-14). HPS2-THRIVE was independently conducted by the Clinical Trial Service Unit at Oxford University, the regulatory sponsor of the trial, and funded by Merck. Merck previously announced that the study did not meet its primary endpoint (December 20, 2012 news release). Adding TREDAPTIVE to statin therapy did not significantly further reduce the risk of major vascular events compared to statin therapy in patients at high risk of cardiovascular events. Additionally, there was a statistically significant","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:40+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130309005046r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/","name":"Results from HPS2-THRIVE Study of TREDAPTIVE\u2122 (extended-release niacin\/laropiprant) Presented at American College of Cardiology Scientific Sessions - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130309005046r1&sid=sfsite1&distro=nx","datePublished":"2013-03-09T12:50:00+00:00","dateModified":"2023-03-22T04:04:40+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130309005046r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130309005046r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-hps2-thrive-study-of-tredaptive-extended-release-niacin-laropiprant-presented-at-american-college-of-cardiology-scientific-sessions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Results from HPS2-THRIVE Study of TREDAPTIVE\u2122 (extended-release niacin\/laropiprant) Presented at American College of Cardiology Scientific Sessions"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"737c54da-c5ab-44c4-8fb1-577e98227228","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743834\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743834"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}